Overview

Study of CS-3150 in Patients With Severe Hypertension

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
To examine antihypertensive effect and safety of administration of CS-3150 in patients with severe hypertension (Grade III).
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Treatments:
Mineralocorticoid Receptor Antagonists